文献速递肝病

Selonsertib治疗NASH相关桥接纤维化或代偿性肝硬化的III期STELLAR试验结果

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
PubMed 文献 · J Hepatol · 2020-03-06

两项随机双盲安慰剂对照III期试验评估Selonsertib(ASK1抑制剂)治疗NASH伴桥接纤维化(F3,STELLAR-3)或代偿性肝硬化(F4,STELLAR-4)患者48周的疗效与安全性。主要终点为48周时纤维化改善≥1期且NASH无恶化,两项试验均未达到主要终点,Selonsertib单药治疗无抗纤维化效果。

要点

  • Selonsertib 18mg或6mg每日一次治疗48周,在NASH伴F3或F4纤维化患者中未达主要终点。
  • STELLAR-3纤维化改善率:18mg组10%、6mg组12%、安慰剂组13%,均无统计学差异。
  • STELLAR-4纤维化改善率:18mg组14%、6mg组13%、安慰剂组13%,均无统计学差异。

核心结论

  • 48周Selonsertib单药治疗对NASH相关桥接纤维化或代偿性肝硬化患者无抗纤维化效果。

研究设计与样本

  • 两项随机、双盲、安慰剂对照III期试验(STELLAR-3和STELLAR-4)。
  • STELLAR-3纳入NASH伴桥接纤维化(F3)患者,STELLAR-4纳入NASH伴代偿性肝硬化(F4)患者。
  • 患者按2:2:1随机接受Selonsertib 18mg、Selonsertib 6mg或安慰剂每日一次,治疗48周。
  • 筛选期和第48周进行肝活检,并评估无创纤维化检测(NITs)。

主要发现

  • STELLAR-3主要终点达成率:Selonsertib 18mg组10%(31/322,vs安慰剂p=0.49),6mg组12%(39/321,p=0.93),安慰剂组13%(21/159)。
  • STELLAR-4主要终点达成率:Selonsertib 18mg组14%(51/354,p=0.56),6mg组13%(45/351,p=0.93),安慰剂组13%(22/172)。
  • Selonsertib导致肝脏磷酸化p38表达呈剂量依赖性降低,提示有药效学活性。
  • Selonsertib对肝脏生化、NITs、肝硬化进展或裁定临床事件无显著影响。
  • 不良事件发生率和类型在Selonsertib组与安慰剂组间相似。

关键数值与推荐

  • 主要疗效终点:第48周纤维化改善≥1期且NASH无恶化的患者比例。
  • STELLAR-3中Selonsertib 18mg组纤维化改善率10%(31/322),6mg组12%(39/321),安慰剂组13%(21/159)。
  • STELLAR-4中Selonsertib 18mg组纤维化改善率14%(51/354),6mg组13%(45/351),安慰剂组13%(22/172)。

临床怎么用

  • 不推荐Selonsertib单药用于NASH相关桥接纤维化或代偿性肝硬化的抗纤维化治疗。
  • 针对ASK1通路的单药抑制在NASH纤维化治疗中未显示临床获益。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Apoptosis signal-regulating kinase 1 (ASK1) plays a key role in hepatocyte injury, inflammation, and fibrosis in non-alcoholic steatohepatitis (NASH). We evaluated the safety and antifibrotic effect of selonsertib, a selective inhibitor of ASK1, in patients with advanced fibrosis due to NASH. METHODS: We conducted 2 randomized, double-blind, placebo-controlled, phase III trials of selonsertib in patients with NASH and bridging fibrosis (F3, STELLAR-3) or compensated cirrhosis (F4, STELLAR-4). Patients were randomized 2:2:1 to receive selonsertib 18 mg, selonsertib 6 mg, or placebo once daily for 48 weeks. Liver biopsies were performed at screening and week 48 and non-invasive tests of fibrosis (NITs) were evaluated. The primary efficacy endpoint was the proportion of patients with ≥1-stage improvement in fibrosis without worsening of NASH at week 48. Additional endpoints included changes in NITs, progression to cirrhosis (in STELLAR-3), and liver-related clinical events. RESULTS: Neither trial met the primary efficacy endpoint. In STELLAR-3, fibrosis improvement without worsening of NASH was observed in 10% (31/322, p = 0.49 vs. placebo), 12% (39/321, p = 0.93 vs. placebo), and 13% (21/159) of patients in the selonsertib 18 mg, selonsertib 6 mg, and placebo groups, respectively. In STELLAR-4, the primary endpoint was achieved in 14% (51/354; p = 0.56), 13% (45/351; p = 0.93), and 13% (22/172) of patients, respectively. Although selonsertib led to dose-dependent reductions in hepatic phospho-p38 expression indicative of pharmacodynamic activity, it had no significant effect on liver biochemistry, NITs, progression to cirrhosis, or adjudicated clinical events. The rates and types of adverse events were similar among selonsertib and placebo groups. CONCLUSIONS: Forty-eight weeks of selonsertib monotherapy had no antifibrotic effect in patients with bridging fibrosis or compensated cirrhosis due to NASH. LAY SUMMARY: Patients with non-alcoholic steatohepatitis (NASH) can develop scarring of the liver (fibrosis), including cirrhosis, which increases the risks of liver failure and liver cancer. We tested whether 48 weeks of treatment with selonsertib reduced fibrosis in patients with NASH and advanced liver scarring. We did not find that selonsertib reduced fibrosis in these patients. TRIAL REGISTRATION DETAILS: Clinicaltrials.gov numbers NCT03053050 and NCT03053063.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020. PMID: 32147362. doi:10.1016/j.jhep.2020.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。